New Study Shows Caldolor by Cumberland Pharmaceuticals Outperforms Ketorolac in Real World AnalysisNASHVILLE, Tenn. (November 5, 2024) – Cumberland Pharmaceuticals (Nasdaq: CPIX) recently disclosed the results of a new study comparing its C

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cumberland Pharmaceuticals’s 8K filing here.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.